Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
The Journal of Headache and Pain
Published in: The Journal of Headache and Pain 1/2013

Open Access 01-12-2013 | Research article

Changes in calcitonin gene-related peptide (CGRP) receptor component and nitric oxide receptor (sGC) immunoreactivity in rat trigeminal ganglion following glyceroltrinitrate pretreatment

Authors: Kristin Seiler, Judith I Nusser, Jochen K Lennerz, Winfried L Neuhuber, Karl Messlinger

Published in: The Journal of Headache and Pain | Issue 1/2013

Login to get access

Abstract

Background

Nitric oxide (NO) is thought to play an important role in the pathophysiology of migraine. Infusion of the nitrovasodilator glyceroltrinitrate (nitroglycerin, GTN), which mobilizes NO in the organism, is an approved migraine model in humans. Calcitonin gene-related peptide (CGRP) is regarded as another key mediator in migraine. Increased plasma levels of CGRP have been found during spontaneous as well as nitrovasodilator-induced migraine attacks. The nociceptive processes and interactions underlying the NO and CGRP mediated headache are poorly known but can be examined in animal experiments. In the present study we examined changes in immunofluorescence of CGRP receptor components (CLR and RAMP1) and soluble guanylyl cyclase (sGC), the intracellular receptor for NO, in rat trigeminal ganglia after pretreatment with GTN.

Methods

Isoflurane anaesthetised rats were intravenously infused with GTN (1 mg/kg) or saline for four hours and two hours later the trigeminal ganglia were processed for immunohistochemistry. Different primary antibodies recognizing CLR, RAMP1, CGRP and sGC coupled to fluorescent secondary antibodies were used to examine immunoreactive cells in serial sections of trigeminal ganglia with epifluorescence and confocal laser scanning microscopy. Several staining protocols were examined to yield optimized immunolabeling.

Results

In vehicle-treated animals, 42% of the trigeminal ganglion neurons were immunopositive for RAMP1 and 41% for CLR. After GTN pretreatment CLR-immunopositivity was unchanged, while there was an increase in RAMP1-immunopositive neurons to 46%. RAMP1 and CLR immunoreactivity was also detected in satellite cells. Neurons immunoreactive for sGC were on average smaller than sGC-immunonegative neurons. The percentage of sGC-immunopositive neurons (51% after vehicle) was decreased after GTN infusion (48%).

Conclusions

Prolonged infusion of GTN caused increased fractions of RAMP1- and decreased fractions of sGC-immunopositive neurons in the trigeminal ganglion. The observed alterations are likely immunophenotypic correlates of the pathophysiological processes underlying nitrovasodilator-induced migraine attacks and indicate that signalling via CGRP receptors but not sGC-mediated mechanisms may be enhanced through endogenous NO production.
Appendix
Available only for authorised users
Literature
1.
Edvinsson L, Elsas T, Suzuki N, Shimizu T, Lee TJ: Origin and Co-localization of nitric oxide synthase, CGRP, PACAP, and VIP in the cerebral circulation of the rat. Microsc Res Tech 2001, 53: 221–228. 10.1002/jemt.1086PubMedCrossRef
2.
Pietrobon D, Striessnig J: Neurobiology of migraine. Nat Rev Neurosci 2003, 4: 386–398. 10.1038/nrn1102PubMedCrossRef
3.
Van Rossum D, Hanisch UK, Quirion R: Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci Biobehav Rev 1997, 21: 649–678. 10.1016/S0149-7634(96)00023-1PubMedCrossRef
4.
Sarchielli P, Alberti A, Codini M, Floridi A, Gallai V: Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks. Cephalalgia 2000, 20: 907–918. 10.1046/j.1468-2982.2000.00146.xPubMedCrossRef
5.
Juhasz G, Zsombok T, Modos EA, Olajos S, Jakab B, Nemeth J, Szolcsanyi J, Vitrai J, Bagdy G: NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain 2003, 106: 461–470. 10.1016/j.pain.2003.09.008PubMedCrossRef
6.
Goadsby PJ, Edvinsson L, Ekman R: Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990, 28: 183–187. 10.1002/ana.410280213PubMedCrossRef
7.
Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J: CGRP may play a causative role in migraine. Cephalalgia 2002, 22: 54–61. 10.1046/j.1468-2982.2002.00310.xPubMedCrossRef
8.
Petersen KA, Lassen LH, Birk S, Lesko L, Olesen J: BIBN4096BS Antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation. Clin Pharmacol Ther 2005, 77: 202–213. 10.1016/j.clpt.2004.10.001PubMedCrossRef
9.
Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM: Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004, 350: 1104–1110. 10.1056/NEJMoa030505PubMedCrossRef
10.
Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones CJ, Lines CR, Rapoport AM: Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 2008, 70: 1304–1312. 10.1212/01.WNL.0000286940.29755.61PubMedCrossRef
11.
Kurosawa M, Messlinger K, Pawlak M, Schmidt RF: Increase of meningeal blood flow after electrical stimulation of rat dura mater encephali: mediation by calcitonin gene-related peptide. Br J Pharmacol 1995, 114: 1397–1402. 10.1111/j.1476-5381.1995.tb13361.xPubMedCentralPubMedCrossRef
12.
Troltzsch M, Denekas T, Messlinger K: The calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS reduces neurogenic increases in dural blood flow. Eur J Pharmacol 2007, 562: 103–110. 10.1016/j.ejphar.2007.01.058PubMedCrossRef
13.
Fischer MJ, Koulchitsky S, Messlinger K: The nonpeptide calcitonin gene-related peptide receptor antagonist BIBN4096BS lowers the activity of neurons with meningeal input in the rat spinal trigeminal nucleus. J Neurosci 2005, 25: 5877–5883. 10.1523/JNEUROSCI.0869-05.2005PubMedCrossRef
14.
Koulchitsky S, Fischer MJ, Messlinger K: Calcitonin gene-related peptide receptor inhibition reduces neuronal activity induced by prolonged increase in nitric oxide in the rat spinal trigeminal nucleus. Cephalalgia 2009, 29: 408–417. 10.1111/j.1468-2982.2008.01745.xPubMedCrossRef
15.
Storer RJ, Akerman S, Goadsby PJ: Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol 2004, 142: 1171–1181. 10.1038/sj.bjp.0705807PubMedCentralPubMedCrossRef
16.
Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W, Muff R, Fischer JA, Foord SM: International union of pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev 2002, 54: 233–246. 10.1124/pr.54.2.233PubMedCrossRef
17.
Evans BN, Rosenblatt MI, Mnayer LO, Oliver KR, Dickerson IM: CGRP-RCP, a novel protein required for signal transduction at calcitonin gene-related peptide and adrenomedullin receptors. J Biol Chem 2000, 275: 31438–31443.PubMedCrossRef
18.
Arulmani U, Maassenvandenbrink A, Villalon CM, Saxena PR: Calcitonin gene-related peptide and its role in migraine pathophysiology. Eur J Pharmacol 2004, 500: 315–330. 10.1016/j.ejphar.2004.07.035PubMedCrossRef
19.
Eftekhari S, Salvatore CA, Calamari A, Kane SA, Tajti J, Edvinsson L: Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience 2010, 169: 683–696. 10.1016/j.neuroscience.2010.05.016PubMedCrossRef
20.
Lennerz JK, Ruhle V, Ceppa EP, Neuhuber WL, Bunnett NW, Grady EF, Messlinger K: Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution. J Comp Neurol 2008, 507: 1277–1299. 10.1002/cne.21607PubMedCrossRef
21.
Thalakoti S, Patil VV, Damodaram S, Vause CV, Langford LE, Freeman SE, Durham PL: Neuron-glia signaling in trigeminal ganglion: implications for migraine pathology. Headache 2007, 47: 1008–1023. 10.1111/j.1526-4610.2007.00854.xPubMedCentralPubMedCrossRef
22.
Olesen J, Thomsen LL, Lassen LH, Olesen IJ: The nitric oxide hypothesis of migraine and other vascular headaches. Cephalalgia 1995, 15: 94–100. 10.1046/j.1468-2982.1995.015002094.xPubMedCrossRef
23.
Reuter U, Bolay H, Jansen-Olesen I, Chiarugi A, del Sanchez RM, Letourneau R, Theoharides TC, Waeber C, Moskowitz MA: Delayed inflammation in rat meninges: implications for migraine pathophysiology. Brain 2001, 124: 2490–2502. 10.1093/brain/124.12.2490PubMedCrossRef
24.
Christiansen I, Thomsen LL, Daugaard D, Ulrich V, Olesen J: Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura. Cephalalgia 1999, 19: 660–667. 10.1046/j.1468-2982.1999.019007660.xPubMedCrossRef
25.
Gibb BJ, Wykes V, Garthwaite J: Properties of NO-activated guanylyl cyclases expressed in cells. Br J Pharmacol 2003, 139: 1032–1040. 10.1038/sj.bjp.0705318PubMedCentralPubMedCrossRef
26.
Kamisaki Y, Saheki S, Nakane M, Palmieri JA, Kuno T, Chang BY, Waldman SA, Murad F: Soluble guanylate cyclase from rat lung exists as a heterodimer. J Biol Chem 1986, 261: 7236–7241.PubMed
27.
Hanafy KA, Krumenacker JS, Murad F: NO, nitrotyrosine, and cyclic GMP in signal transduction. Med Sci Monit 2001, 7: 801–819.PubMed
28.
Behrends S, Knyihar-Csillik E, Kempfert J, Scholz H, Csillik B, Vecsei L: Glyceryl trinitrate treatment up-regulates soluble guanylyl cyclase in rat dura mater. Neuroreport 2001, 12: 3993–3996. 10.1097/00001756-200112210-00028PubMedCrossRef
29.
Dieterle A, Fischer MJ, Link AS, Neuhuber WL, Messlinger K: Increase in. Cephalalgia 2011, 31: 31–42. 10.1177/0333102410375725PubMedCrossRef
30.
Koulchitsky S, Fischer MJ, De CR, Schlechtweg PM, Messlinger K: Biphasic response to nitric oxide of spinal trigeminal neurons with meningeal input in rat–possible implications for the pathophysiology of headaches. J Neurophysiol 2004, 92: 1320–1328. 10.1152/jn.01210.2003PubMedCrossRef
31.
Collins JJ, Wilson K, Fischer-Colbrie R, Papka RE: Distribution and origin of secretoneurin-immunoreactive nerves in the female rat uterus. Neuroscience 2000, 95: 255–264.PubMedCrossRef
32.
Raab M, Neuhuber WL: Vesicular glutamate transporter 2 immunoreactivity in putative vagal mechanosensor terminals of mouse and rat esophagus: indication of a local effector function? Cell Tissue Res 2003, 312: 141–148.PubMed
33.
Wank M, Neuhuber WL: Local differences in vagal afferent innervation of the rat esophagus are reflected by neurochemical differences at the level of the sensory ganglia and by different brainstem projections. J Comp Neurol 2001, 435: 41–59. 10.1002/cne.1192PubMedCrossRef
34.
Dimitriadou V, Rouleau A, Trung Tuong MD, Newlands GJ, Miller HR, Luffau G, Schwartz JC, Garbarg M: Functional relationships between sensory nerve fibers and mast cells of dura mater in normal and inflammatory conditions. Neuroscience 1997, 77: 829–839. 10.1016/S0306-4522(96)00488-5PubMedCrossRef
35.
Ma QP: The expression of bradykinin B(1) receptors on primary sensory neurones that give rise to small caliber sciatic nerve fibres in rats. Neuroscience 2001, 107: 665–673. 10.1016/S0306-4522(01)00387-6PubMedCrossRef
36.
Sun YG, Chen ZF: A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. Nature 2007, 448: 700–703. 10.1038/nature06029PubMedCrossRef
37.
McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, Foord SM: RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 1998, 393: 333–339. 10.1038/30666PubMedCrossRef
38.
Ding JD, Burette A, Nedvetsky PI, Schmidt HH, Weinberg RJ: Distribution of soluble guanylyl cyclase in the rat brain. J Comp Neurol 2004, 472: 437–448. 10.1002/cne.20054PubMedCrossRef
39.
Ashina M, Simonsen H, Bendtsen L, Jensen R, Olesen J: Glyceryl trinitrate may trigger endogenous nitric oxide production in patients with chronic tension-type headache. Cephalalgia 2004, 24: 967–972. 10.1111/j.1468-2982.2004.00780.xPubMedCrossRef
40.
Davis JP, Vo XT, Sulakhe PV: Altered responsiveness of guanylyl cyclase to nitric oxide following treatment of cardiomyocytes with S-nitroso-D, L-acetylpenicillamine and sodium nitroprusside. Biochem Biophys Res Commun 1997, 238: 351–356. 10.1006/bbrc.1997.7278PubMedCrossRef
41.
Papapetropoulos A, Go CY, Murad F, Catravas JD: Mechanisms of tolerance to sodium nitroprusside in rat cultured aortic smooth muscle cells. Br J Pharmacol 1996, 117: 147–155. 10.1111/j.1476-5381.1996.tb15167.xPubMedCentralPubMedCrossRef
42.
Ujiie K, Hogarth L, Danziger R, Drewett JG, Yuen PS, Pang IH, Star RA: Homologous and heterologous desensitization of a guanylyl cyclase-linked nitric oxide receptor in cultured rat medullary interstitial cells. J Pharmacol Exp Ther 1994, 270: 761–767.PubMed
43.
Filippov G, Bloch DB, Bloch KD: Nitric oxide decreases stability of mRNAs encoding soluble guanylate cyclase subunits in rat pulmonary artery smooth muscle cells. J Clin Invest 1997, 100: 942–948. 10.1172/JCI119610PubMedCentralPubMedCrossRef
44.
Sardon T, Baltrons MA, Garcia A: Nitric oxide-dependent and independent down-regulation of NO-sensitive guanylyl cyclase in neural cells. Toxicol Lett 2004, 149: 75–83. 10.1016/j.toxlet.2003.12.021PubMedCrossRef
45.
Tassorelli C, Joseph SA: NADPH-diaphorase activity and Fos expression in brain nuclei following nitroglycerin administration. Brain Res 1995, 695: 37–44. 10.1016/0006-8993(95)00732-6PubMedCrossRef
46.
Messlinger K, Lennerz JK, Eberhardt M, Fischer MJ: CGRP and NO in the trigeminal system: mechanisms and role in headache generation. Headache 2012, 52: 1411–1427. 10.1111/j.1526-4610.2012.02212.xPubMedCrossRef
Metadata
Title
Changes in calcitonin gene-related peptide (CGRP) receptor component and nitric oxide receptor (sGC) immunoreactivity in rat trigeminal ganglion following glyceroltrinitrate pretreatment
Authors
Kristin Seiler
Judith I Nusser
Jochen K Lennerz
Winfried L Neuhuber
Karl Messlinger
Publication date
01-12-2013
Publisher
Springer Milan
Published in
The Journal of Headache and Pain / Issue 1/2013
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI
https://doi.org/10.1186/1129-2377-14-74

Other articles of this Issue 1/2013

The Journal of Headache and Pain 1/2013 Go to the issue

Letter to the Editor

Modified Valsalva test differentiates primary from secondary cough headache

Research article

The impact of headache and chronic musculoskeletal complaints on the risk of insomnia: longitudinal data from the Nord-Trøndelag health study

Research article

Lidocaine injection of pericranial myofascial trigger points in the treatment of frequent episodic tension-type headache

Research article

Phospholipase C activity increases in cerebrospinal fluid from migraineurs in proportion to the number of comorbid conditions: a case–control study

Editorial

The Global Burden of Disease survey 2010, Lifting The Burden and thinking outside-the-box on headache disorders

Research article

Botulinum toxin-type A: could it be an effective treatment option in intractable trigeminal neuralgia?